Opemalirsen (AZD2373) Clinical Trials (2026): 1 Studies for Renal Impairment
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 Opemalirsen (AZD2373) clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Renal Impairment) and 34 total planned enrollment. Most recent activity: NCT07154901 (Jun 2026).
Opemalirsen (AZD2373) clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
All Opemalirsen (AZD2373) trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07154901 | AZD2373 | Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373) | P1 | active not recruiting | 34 | AstraZeneca | Aug 2025 |
Opemalirsen (AZD2373) clinical trials: frequently asked questions
- How many Opemalirsen (AZD2373) clinical trials are there?
- 1 Opemalirsen (AZD2373) clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov.
- Are Opemalirsen (AZD2373) clinical trials recruiting in 2026?
- No active Opemalirsen (AZD2373) trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Opemalirsen (AZD2373) being studied for?
- Opemalirsen (AZD2373) is being studied for Renal Impairment. The trials are grouped by indication on this page.
- What phase is Opemalirsen (AZD2373) in?
- Opemalirsen (AZD2373) clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Opemalirsen (AZD2373) clinical trials?
- The lead sponsor across the most Opemalirsen (AZD2373) trials is AstraZeneca. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Opemalirsen (AZD2373)as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: